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Objective: To evaluate exercise test responses in hypokalae-
mic periodic paralysis (HPP), to determine its value as a
diagnostic tool and the factors that could affect the responses.
Methods: 22 subjects were studied from two families with
HPP caused by R528H mutation, four patients with thyrotoxic
periodic paralysis, 15 normal controls, and four controls with
hyperthyroidism. All family members were submitted to
clinical evaluation, electrophysiological exercise testing, and
DNA analysis. Patients with thyrotoxic periodic paralysis had
exercise tests before and after treatment of their hyperthyr-
oidism.
Results: Abnormal responses to the exercise tests were
obtained only in subjects with recent attacks of weakness.
They were not correlated with genotype, as asymptomatic
carriers were unaffected. Patients with thyrotoxic periodic
paralysis showed pronounced impairment while they were
hyperthyroid, but improved when they were euthyroid. One
patient with HPP and chronic KCl use had an increase in
amplitude potentials over ,20 minutes, possibly related to
alteration of potassium homeostasis.
Conclusions: The exercise test is a useful diagnostic test for
periodic paralysis, but in the absence of recent weakness
negative results must be viewed with caution. It has
advantages over the DNA test in being a non-invasive
functional test that can provide insights into abnormalities of
muscle excitability.
F
amilial hypokalaemic periodic paralysis (HPP) is char-
acterised by episodes of flaccid weakness associated with
low serum potassium levels. The disease is caused by
mutations in one of the calcium channel (a1S) genes
(R528H,1 R1239H, or R1239G2 3) leading to abnormal muscle
excitability. Another form of hypokalaemic periodic paralysis,
usually sporadic, is associated with hyperthyroidism (thyr-
otoxic periodic paralysis), with attacks of weakness that are
similar to those in the familial forms but which occur only
during hyperthyroidism and are completely abolished when
thyroid hormone levels are normalised.
As compound muscle action potential (CMAP) amplitude
decreases during muscle weakness and as exercise can induce
weakness during periodic paralysis, an electrophysiological
exercise test has been proposed as a diagnostic tool.4 After
strong muscle contraction for two to five minutes, an
abnormal reduction in CMAP amplitudes is seen during
asymptomatic periods in all forms of periodic paralysis. High
specificity (97.8%)5 has been reported, but sensitivity has
varied between studies (for example, 82%5 and 54%4).
Variation in sensitivity could be explained by an incorrect
diagnosis of periodic paralysis, by the influence of treatment,
by the fluctuating nature of the disease with periodic
improvements in muscle excitability, or by variations in the
application of the method. Although exercise testing has
been reported in several studies,5–9 the factors affecting the
responses were not specifically evaluated. The sensitivity of
exercise tests for detecting asymptomatic carriers is also
unknown. Asymptomatic carriers have been detected by
abnormalities in muscle fibre conduction velocity,10 but
carrier status was not confirmed by DNA analysis and no
changes were observed with acetazolamide treatment.11
Apart from the use of the exercise test as a diagnostic tool,
the normalisation of the responses observed in thyrotoxic
periodic paralysis after correction of hyperthyroidism7 sug-
gests that the test may also be an indicator of disease status
and could reflect muscle excitability. Improvement in muscle
excitability seems to occur in periodic paralysis, as the
frequency of paralytic attacks declines after the age of 30
years and in most cases attacks cease after 50 years.11
Our aim in this study was to evaluate exercise test
responses in HPP in relation to clinical status, genotype,
and treatment, and to determine its value as a diagnostic tool
and the factors that could affect the responses.
METHODS
Patients and controls
We evaluated 22 individuals (two families) with HPP caused
by the R528H mutation (genotyping was done in all these),
four patients with thyrotoxic periodic paralysis, four controls
with hyperthyroidism, and 15 normal controls (volunteers).
Index patients with periodic paralysis had a typical clinical
history and a low serum potassium during weakness.
All family members were submitted to a clinical evalua-
tion, electrophysiological exercise testing, and DNA analysis.
Patients with thyrotoxic periodic paralysis had hyperthyroid-
ism confirmed by laboratory analysis and were submitted to
exercise test before and after treatment of their hyperthyr-
oidism (successful treatment confirmed by normal hormone
levels). Clinical evaluation was undertaken by one of us
(CHT).
Exercise test
The test was always done during an inter-attack period when
muscle strength was normal. The hand was immobilised on
an arm board to minimise artefactual changes in CMAP
amplitude resulting from electrode movement.
Supramaximal stimulation of ulnar nerve was obtained with
a bipolar stimulator attached to the wrist. Using standard
techniques and surface electrodes, CMAPs in the abductor
digiti minimi were recorded every minute for five minutes to
obtain baseline amplitude. The patient was then asked to
contract the muscle isometrically for five minutes as hard as
possible. At the completion of the exercise, the patient was
instructed to relax completely while CMAP responses to
single shocks were recorded every minute until stabilisation
of the decrement (40 to 50 minutes). After recording two to
three responses, one stimulus with larger intensity was
applied to check for the adequacy of the stimulation. The
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percentage changes in amplitude were calculated according
to McMannis et al.4
The study was approved by the ethics committee of
Universidade Federal de Sa˜o Paulo and was in accordance
with the ethical standards of the Helsinki Declaration of
1975.
RESULTS
CMAP amplitude decrement was not influenced by age or sex
and varied from 5.4% to 28.8% (mean 15%) in the control
group. The R528H mutation was found in 14 individuals: four
asymptomatic carriers (who had never had symptoms) and
10 affected subjects (with at least one well characterised
transient attack of weakness). Affected subjects could be
classified into two groups: those with recent attacks (attacks
in a period of less than one year before the test), and those
with previous attacks (attacks in the past but no symptoms
for at least one year). Affected subjects with recent attacks
(n = 6) showed more pronounced decrements (31.1% to
64.3%), while the subjects with previous attacks had
decrements similar to the control group (below 30%). All
other subjects, carriers or non-carriers, were completely
asymptomatic and showed responses below 30%. All patients
with thyrotoxic periodic paralysis had recent clinical attacks
and showed more pronounced decrements in CMAP ampli-
tudes (46.8–66.8%) while they were in the hyperthyroid state,
with normalisation of the responses after returning to the
euthyroid state (fig 1A).
The exercise test had a sensitivity of 55% and a specificity
of 97% on the basis of the following: confirmation of the
disease by identifying the R528H mutation or by the presence
of thyrotoxic periodic paralysis; and the definition of a
normal exercise test response as a decrement below 29%
(mean +2 SD of values from normal controls and hyperthyr-
oid controls). However, sensitivity increased to 100% when
we included the occurrence of recent attacks in the definition
of the disease.
While retesting was done in all patients with thyrotoxic
periodic paralysis, it was carried out in only one patient with
FPP, who had a different pattern of response from the rest
(fig 1B). This patient had almost daily attacks and had a
decrement of only 31.1% with the use of high doses of
potassium chloride (KCl) daily. Other drugs, including
carbonic anhydrase inhibitors, had been discontinued
because of side effects. The use of KCl improved muscle
weakness during attacks and allowed the patient to carry on
a normal level of daily activities. Recently the patient
developed more severe attacks even with KCl, but with
normal muscle strength during the inter-attack period.
Serum potassium was 5.5 mmol/l and on the same day, a
second exercise test showed a rapid decrement (25%) during
the first seven minutes after exercise, followed by increase in
amplitude (16%) over the next 25 minutes. Reviewing the
first test in this patient, we saw that the same type of
response was already present at that time, but was less
pronounced.
No other preventive drugs were used by the familial cases.
KCl was used sporadically by two other subjects during
attacks. These patients showed decrements of 45.5% and 67%
and did not take KCl before the test.
DISCUSSION
Our study clearly shows that an abnormal response on
exercise testing was correlated with disease status and not
genotype. Because of incomplete penetrance in women, the
presence of the R528H mutation is not a good indicator of
disease activity,12 which can be predicted by the exercise test.
As a diagnostic tool, exercise testing had high specificity but
low sensitivity (55%) when defining the presence of the
disease by genotype alone, given that normal responses were
obtained in asymptomatic carriers and affected subjects with
previous attacks. However, sensitivity increases to 100%
when recent symptoms are included along with the genotype
in defining the presence of disease. This is important because
if the patient is evaluated for a diagnosis of periodic paralysis,
usually following a recent complaint of weakness, the
exercise test is a good diagnostic test, while in the absence
of recent weakness or with chronic use of KCl, negative
results must be viewed with caution. The correlation between
exercise test results and disease status was confirmed by the
Figure 1 Responses obtained on the exercise test in hypokalaemic
periodic paralysis. (A) Asymptomatic carriers and affected subjects with
previous attacks had decrements similar to controls, while larger
decrements were observed in affected subjects with recent attacks and in
patients with thyrotoxic periodic paralysis (TPP–before). After treatment,
patients with thyrotoxic periodic paralysis (TPP–after) showed
decrements in compound muscle action potential (CMAP) amplitudes
similar to control responses. Controls with hyperthyroidism (Ctrl–tireo)
but no history of periodic weakness showed decrements of less than
30%. Horizontal line in the box are medians; top and bottom edges of
the box are 25th and 75th centiles; error bars are¡1.56 interquartile
range; unfilled dots are outliers. (B) Typical exercise test response is
characterised by a slight increase in CMAP amplitude after exercise,
followed by a progressive decline in amplitudes until stabilisation. One
of the patients showed a new type of response, with a rapid decrement
(25%) during the first seven minutes after exercise, followed by a 16%
increase in amplitude over the next 25 minutes until stabilisation. Results
of CMAP amplitudes are expressed as a percentage, where 100% is the
mean of CMAP amplitudes obtained during the pre-exercise period.
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normalisation of responses in thyrotoxic periodic paralysis
after euthyroidism was achieved. The abnormality detected in
thyrotoxic periodic paralysis is not caused by hyperthyroid-
ism per se, as controls with hyperthyroidism but without
periodic paralysis have normal responses. Our results suggest
that thyrotoxic periodic paralysis may be caused by a muscle
excitability abnormality that is only unmasked by hyperthyr-
oidism.
To our knowledge, the new type of response observed in
one of our patients has not been described before in any
myopathy, and was characterised by increased CMAP
amplitudes over 20 minutes. The typical response on exercise
testing involves a decline in CMAP amplitudes as the
predominant alteration, with increased amplitudes observed
only during the first minutes after the exercise.4 The only
feature that distinguished this patient from the others was
the chronic use of KCl; thus we speculate that excessive KCl
might have led to abnormalities of K+ homeostasis causing
this unexpected response. Involvement of KATP channels in
the pathophysiology of HPP has already been suggested to
explain the hypokalaemia and membrane depolarisation in
this condition13; however, factors controlling potassium
channels are still not completely understood. On the basis
of modulation of potassium channels by slight changes in
extracellular K+,14 and the observation of increased CMAP
amplitude in hyperpolarised membranes,15 16 a possible
explanation for our finding is that chronic KCl intake
increases extracellular K+, leading to an increase in potas-
sium channels and excessive potassium outflux. The muscle
membrane thus become hyperpolarised, making it more
difficult for a stimulus to provoke an action potential. This
process is manifested as muscle weakness.
Our study shows that the exercise test is a useful and
sensitive diagnostic test for periodic paralysis in the presence
of recent symptoms and no treatment. Its advantages over
the DNA test are that it is a non-invasive functional test that
can also provide insights into abnormalities of muscle
excitability in this disease. It is easily carried out with
standard electrophysiological equipment and techniques.
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